3 Funky Useful Information On Quetiapine

2% vs. 38.2%; P AG-014699 in vivo frequency of motor fluctuations (35.53% vs. 22.22%; P = 0.016) and the levodopa equivalent dose (LED) values were also significantly higher in the carrier group (553.67 �� 329.84 vs. 467.71 �� 286.34; P = 0.016; Table 1). Table 1 Comparison of the demographic and motor characteristics of LRRK2 G2385R variant carrier and non- carrier PD patients Table 2 Comparison of non-motor symptoms in LRRK2 G2385R variant carrier and non-carrier PD patients Additionally, analysis of the non-motor symptoms between the two groups revealed that the G2385R variant carrier group had significantly higher mean RBDSQ scores (5.00 �� 3.21 vs. 3.87 ��2.91; P = 0.003) and the number of subjects with a RBDSQ score �� 6 (44.74% vs. 28.44%; P = 0.006) than in the non-carrier group, after adjusting for age and sex. Although the mean MMSE score was higher in the G2385R variant carrier group (27.78 �� 2.68 vs. 26.96 �� 2.92; P = 0.034), the frequency of cognitive impairment did not reach statistical significance between the two groups (1.32% vs. 6.22%; P = 0.089). There were no significant differences between the LRRK2 G2385R variant LDK378 mw carriers and non-carriers with respect to the scores for NMSQuest, SCOPA-AUT, SS-16 and HAMD-17. Simultaneously, the frequency of hyposmia, depression and constipation in carriers did not significantly differ from that in non-carriers. DISCUSSION The LRRK2 G2385R variant is the most Quetiapine commonly occurring pathogenic LRRK2 substitution in Chinese populations. In our study, this variant was observed at a frequency of 11.3% in PD patients, which was consistent with the results of other studies in Asian populations (range, 5.7-11.9%) [3, 7, 9, 19-22]. Despite extensive study, the role of the LRRK2 G2385R variant in the development of PD remains unclear. This study was carried out to determine whether the LRRK2 G2385R variant was associated with unique phenotypic characteristics within a PD patient population. Our findings indicated that while non-carriers showed a higher prevalence of the TD subtype, LRRK2 G2385R variant carriers were more likely to manifest the PIGD motor subtype, which was associated with an increased mortality risk, accelerated cognitive decline, greater severity of autonomic symptoms, and greater functional disability when compared with the TD phenotype [10, 23-25]. In addition, the frequency of motor fluctuations and the LED values were also significantly higher in the G2385R variant carrier group. Our findings also showed that the mean RBDSQ score and the number of subjects with RBD symptoms were significantly higher in the G2385R variant carrier group than in the non-carrier group.